NKARTA INC
NKTXNASDAQ🏆 #3868 by market capEarnings Nov 11US Equity
$1.71▼ $0.03 (−1.45%)
Latest quoteTrack NKTX
Get earnings, price moves & breaking news on Telegram
24h▼ 1.4%
7d▼ 2.0%
14d▼ 11.4%
30d▼ 35.0%
ytd▼ 7.6%
1y▼ 17.8%
🏦Market Cap
$122M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Fair
Trading Snapshot
- Day Range
- $1.70 – $1.75
- 52-Week Range
- $1.58 – $3.72
- Volume (shares)
- 17,483
- Avg Volume (shares)
- —
- Shares Outstanding
- 71.6M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -1.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.57
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.6%
NKARTA INC
NKTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$121M▼ −5.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$90M▼ −13.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.0M▲ +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$37M▲ +$16M YoY
StockOtter · stockotter.spaceAbout NKARTA INC
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
52/100
Analyst data unavailable.
Latest News & Updates
News unavailable.